NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

FibroGen Inc (MX: FGEN)

 
FGEN Technical Analysis
4
As on 9th Dec 2025 FGEN STOCK Price closed @ 155.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 23.85 & Strong Buy for SHORT-TERM with Stoploss of 9.44 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

FGENSTOCK Price

Open 155.00 Change Price %
High 155.00 1 Day 6.00 4.03
Low 155.00 1 Week -44.96 -22.48
Close 155.00 1 Month 148.80 2400.00
Volume 115 1 Year 147.10 1862.03
52 Week High 223.00 | 52 Week Low 5.08
 
MX Mexico Most Active Stocks
AMXL 19.28 -0.36%
PV 8.50 7.32%
CEMEXCPO 22.19 0.54%
FR 669.01 0.28%
ALFAA 15.37 -2.04%
BBAJIOO 47.94 1.72%
GMEXICOB 199.65 2.90%
RLHA 16.50 -1.49%
WALMEX 58.29 0.71%
FMTY14 15.20 -0.39%
 
MX Mexico Top Gainers Stocks
ALEATIC 49.86 141.69%
MKSN 54.86 92.49%
GNW 160.21 57.38%
GNW 160.21 57.38%
KPNN 84.19 36.76%
KMX 810.00 14.89%
KMX 810.00 14.89%
LYGN 94.00 14.63%
HBCN 1459.50 12.79%
LEA 2120.00 11.58%
 
MX Mexico Top Losers Stocks
AGLN 502.53 -25.55%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
PPG 1822.26 -22.62%
PPG 1822.26 -22.62%
PPG 1822.26 -22.62%
PPG 1822.26 -22.62%
 
 
FGEN
Daily Charts
FGEN
Intraday Charts
Whats New @
Bazaartrend
FGEN
Free Analysis
 
FGEN Important Levels Intraday
RESISTANCE155.00
RESISTANCE155.00
RESISTANCE155.00
RESISTANCE155.00
RESISTANCE155.00
RESISTANCE155.00
RESISTANCE155.00
RESISTANCE155.00
 
FGEN Forecast January 2026
4th UP Forecast175.04
3rd UP Forecast168.61
2nd UP Forecast164.64
1st UP Forecast160.67
1st DOWN Forecast149.33
2nd DOWN Forecast145.36
3rd DOWN Forecast141.39
4th DOWN Forecast134.96
 
FGEN Weekly Forecast
4th UP Forecast169.36
3rd UP Forecast164.75
2nd UP Forecast161.91
1st UP Forecast159.06
1st DOWN Forecast150.94
2nd DOWN Forecast148.09
3rd DOWN Forecast145.25
4th DOWN Forecast140.64
 
FGEN Forecast2026
4th UP Forecast578.94
3rd UP Forecast442.98
2nd UP Forecast358.94
1st UP Forecast274.9
1st DOWN Forecast35.1
2nd DOWN Forecast-48.94
3rd DOWN Forecast-132.98
4th DOWN Forecast-268.94
 
 
FGEN Other Details
Segment EQ
Market Capital 21147756544.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
FGEN Address
FGEN
 
FGEN Latest News
 
Your Comments and Response on FibroGen Inc
 
FGEN Business Profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 409 Illinois Street, San Francisco, CA, United States, 94158
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service